-
Product Insights
NewPediatric Cancer – Drugs In Development, 2024
Empower your strategies with our Pediatric Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Pediatric cancer types include leukemias, brain and other central nervous system (CNS) tumors, and lymphomas. Signs and symptoms include unexplained paleness and loss of energy, easy bruising or bleeding, limping, fever, and headaches. Diagnosis can be done by blood tests, biopsy, ultrasound, MRI, and PET-CT scan. Common treatments include surgery, chemotherapy, radiation therapy, immunotherapy, and stem cell transplant. The Pediatric Cancer drugs...
-
Product Insights
NewAnaplastic Astrocytoma – Drugs In Development, 2024
Empower your strategies with our Anaplastic Astrocytoma – Drugs In Development, 2024 report and make more profitable business decisions. Anaplastic astrocytoma is a grade III tumor that accounts for 2% of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking,...
-
Product Insights
NewRhabdomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Rhabdomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy,...
-
Product Insights
NewMalignant Glioma – Drugs In Development, 2024
Empower your strategies with our Malignant Glioma – Drugs In Development, 2024 report and make more profitable business decisions. Malignant gliomas are aggressive and fast-growing tumors that arise from glial cells in the brain and spinal cord. Gliomas account for the most common type of primary brain tumors in adults. Symptoms of malignant gliomas vary depending on the tumor's size, location, and rate of growth. Common symptoms may include headaches, seizures, cognitive changes, personality or behavior changes, weakness or sensory loss,...
-
Product Insights
NewMedulloblastoma – Drugs In Development, 2024
Empower your strategies with our Medulloblastoma – Drugs In Development, 2024 report and make more profitable business decisions. Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occurs in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting, and difficulty with walking and balance. Medulloblastoma can spread to...
-
Product Insights
NewEwing Sarcoma – Drugs In Development, 2024
Empower your strategies with our Ewing Sarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Ewing sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing sarcoma can occur at any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site...
-
Product Insights
NewBrain Cancer – Drugs In Development, 2024
Empower your strategies with our Brain Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Brain cancer refers to the abnormal growth of cells in the brain, forming tumors that can be benign (non-cancerous) or malignant (cancerous). Primary brain tumors originate in the brain itself, while secondary tumors result from the spread of cancer from other parts of the body. Symptoms may include headaches, seizures, changes in behavior, and cognitive impairment. Diagnosis involves imaging studies like MRI...
-
Product Insights
NewNeuroblastoma – Drugs In Development, 2024
Empower your strategies with our Neuroblastoma – Drugs In Development, 2024 report and make more profitable business decisions. Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest, or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands before spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include a lump in the abdomen or chest, weakness, bone pain, breathing problems, dark...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine 2 in Tetanus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine 2 in Tetanus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LUNA-18 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LUNA-18 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LUNA-18 in Solid Tumor Drug Details: LUNA-18 is under development for...